Liisa I. Nogelo
Keine laufenden Positionen mehr
Karriereverlauf von Liisa I. Nogelo
Ehemalige bekannte Positionen von Liisa I. Nogelo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BIOGEN INC. | Corporate Officer/Principal | 01.09.2007 | 01.07.2018 |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | General Counsel | 01.08.2014 | 01.07.2018 |
SURFACE ONCOLOGY, INC. | General Counsel | 01.07.2018 | 01.02.2022 |
Corporate Officer/Principal | 01.02.2022 | - | |
Unternehmenssekretär | 01.01.2020 | 01.02.2022 |
Ausbildung von Liisa I. Nogelo
Wellesley College | Undergraduate Degree |
UCLA School of Law | Graduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
General Counsel | 2 |
Corporate Officer/Principal | 2 |
Corporate Secretary | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BIOGEN INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Liisa I. Nogelo
- Erfahrung